FGFR3 and skeletal dysplasia: In addition, for the general short-stature population with skeletal dysplasia, ACAN-related short stature was more responsive to rhGH treatment than NPR2-related short stature, and significant height improvement was not seen in FGFR3-related short-stature patients in this cohort.